We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
First Natural Brands is the owner of Tisserand Aromatherapy, one of the leading self-governing players in UK’s essential oil industry. It offers a variety of affordable organic and quality accredited products which consumers can relish as part of their daily lifestyle. Tisserand Aromatherapy is experiencing a growing interest among media, retail and consumers. Since 2007, the company’s sales have increased from £1.7mn to £6mn, owing to Robin Russell (CEO & Chairman) for bringing Tisserand into the mainstream market with a value for money proposition. Further investment will allow the company to expand its production capacity.
days to go: Expired investment: £325,660
The House of Wings (THOW) is a pop-up restaurant that specialises in a variety of different flavour wings. With the use of the proceeds raised, THOW are looking to open their first permanent restaurant in a high footfall location in West London.
days to go: Expired investment: £8,817
Occuity seeks to develop revolutionary non-invasive screening and monitoring devices for chronic diseases like diabetes and Alzheimer's. It argues that its device safely shines a low power beam of light into the eye and then collects and analyses the return signal to accurately measure structures within the eye and detect changes associated with the onset of the aforementioned diseases. Occuity is targeting three distinct markets, namely Ophthalmology, Disease Screening and Disease Monitoring, which is worth an estimated $35 billion per year. It claims that its 'Occuity Indigo' product enables earlier detection of diabetes and provides a non-contacting, pain-free glucose monitor. Occuity was awarded over £1.5 million as part of the Innovate UK grant for the development of technology within Occuity Indigo. It has also signed a partnership with one of the UK's leading ophthalmic distributors, Birmingham Optical, to distribute its PM1 pachymeter device. It states it will use 42% of the investment towards Research and Development (R&D), 23% towards sales and marketing, 20% towards management and finance, 9% towards managing CAPEX and NRE, and 6% towards paying fees.
days to go: Expired investment: £2,854,857
StarStock are a drinks marketplace that enable suppliers to sell direct to wholesalers, pubs, shops, bars & restaurants nationwide. StarStock puts the suppliers in control of their products and listings, taking a small percentage of each sale. Suppliers set the prices, while we do the rest, arranging delivery of beers, ciders, wine and spirits.
days to go: Expired investment: £1,343,149
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph